Dyne Therapeutics, Inc.
Undisclosed program
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Undisclosed program for its lead indication around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“completed a positive pre-BLA meeting with the U.S. Food and Drug Administration (FDA) and remains on track to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026.”